Phototoxic reaction and porphyrin fluorescence in skin after topical application of methyl aminolaevulinate

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 301-307

  Angell Petersen, E ^a   Christensen, C ^a   Muller C R ^a   Warloe, T ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aminolaevulinic acid; Fluorescence; Methyl aminolaevulinate; Photodynamic therapy; Phototoxicity; Skin photosensitivity

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; PHOTOSENSITIZING AGENT; PLACEBO; PORPHYRIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DRUG METABOLISM; DRUG SAFETY; ERYTHEMA; FEMALE; FINGER TIP INJURY; FLUORESCENCE IN SITU HYBRIDIZATION; FOREARM; HUMAN; HYPERPIGMENTATION; LIGHT EXPOSURE; MAJOR CLINICAL STUDY; MALE; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; RED LIGHT; SKIN DISEASE; SKIN EDEMA; SKIN MANIFESTATION; SKIN PAIN; SKIN SENSITIVITY;

ADMINISTRATION, TOPICAL; ADULT; AMINOLEVULINIC ACID; DERMATITIS, PHOTOTOXIC; DOUBLE-BLIND METHOD; FEMALE; FLUORESCENCE; HUMANS; MALE; OINTMENTS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 33846230997     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07638.x     Document Type: Article

References (45)

1. Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol 2000; 1:212-19.
2. Weersink RA, Forbes J, Bisland S et al. Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol 2005; 81:106-13.
3. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5:497-508.
4. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6:143-8.
5. Malik Z, Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br J Cancer 1987; 56:589-95.
6. Peng Q, Evensen JF, Rimington C, Moan J. A comparison of different photosensitizing dyes with respect to uptake C3H-tumors and tissues of mice. Cancer Lett 1987; 36:1-10.
7. Peng Q, Berg K, Moan J et al. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 1997; 65:235-51.
8. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146:552-67.
9. Golub AL, Gudgin DE, Kennedy JC et al. The monitoring of ALA-induced protoporphyrin IX accumulation and clearance in patients with skin lesions by in vivo surface-detected fluorescence spectroscopy. Lasers Med Sci 1999; 14:112-22.
10. Regula J, MacRobert AJ, Gorchein A et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX - a pilot study. Gut 1995; 36:67-75.
11. Endlicher E, Knuechel R, Hauser T et al. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut 2001; 48:314-19.
12. Peng Q, Warloe T, Moan J et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995; 62:906-13.
13. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? J Am Acad Dermatol 1993; 28:17-21.
14. Martin A, Tope WD, Grevelink JM et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995; 287:665-74.
15. Peng Q, Moan J, Nesland JM. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol 1996; 20:109-29.
16. Kloek J, Beijersbergen van Henegouwen GM. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol 1996; 64:994-1000.
17. Fotinos N, Campo MA, Popowycz F et al. 5-Aminolevulinic acid derivatives in photomedicine: basics, application and perspectives. Photochem Photobiol 2006; 82:994-1015.
18. Szeimies RM, Karrer S, Radakovic-Fijan S et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47:258-62.
19. Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14:99-106.
20. Pariser DM, Lowe NJ, Stewart DM et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48:227-32.
21. Morton CA, Horn M, Leman J et al. A placebo controlled European study comparing MAL-PDT with cryotherapy and 5-fluoracil in patients with Bowen's disease. J Eur Acad Dermatol Venereol 2004; 18:415 (Abstract).
22. Soler AM, Warloe T, Berner A et al. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145:467-71.
23. Horn M, Wolf P, Wulf HC et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003; 149:1242-9.
24. Rhodes LE, de Rie M, Enström Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140:17-23.
25. Vinciullo C, Elliott T, Francis D et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152:765-72.
26. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006; 154:969-75.
27. Fritsch C, Homey B, Stahl W et al. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998; 68:218-21.
28. Thompson MS, Gustafsson L, Palsson S et al. Photodynamic therapy and diagnostic measurements of basal cell carcinomas using esterified and non-esterified delta-aminolevulinic acid. J Porphyrins Phthalocyanines 2001; 5:147-53.
29. Angell-Petersen E, Sørensen R, Warloe T et al. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006; 126:265-71.
30. Wiegell SR, Stender IM, Na R et al. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003; 139:1173-7.
31. Newcombe RG. Confidence intervals for the mean of a variable taking the values 0, 1 and 2. Stat Med 2003; 22:2737-50.
32. Gaullier JM, Berg K, Peng Q et al. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 1997; 57:1481-6.
33. Tunstall RG, Barnett AA, Schofield J et al. Porphyrin accumulation induced by 5-aminolaevulinic acid esters in tumour cells growing in vitro and in vivo. Br J Cancer 2002; 87:246-50.
34. Moan J, Ma LW, Juzeniene A et al. Pharmacology of protoporphyrin IX in nude mice after application of ALA and ALA esters. Int J Cancer 2003; 103:132-5.
35. Juzenas P, Sørensen R, Iani V et al. Clearance of protoporphyrin IX from mouse skin after topical application of 5-aminolevulinic acid and its methyl ester. In: Proceedings of SPIE Vol. 3563, Photochemotherapy of Cancer and Other Diseases (Ehrenberg B, Berg K, eds). Bellingham, WA: The International Society for Optical Engineering, 1999;161-6.
36. Juzeniene A, Juzenas P, Ma LW et al. Topical application of 5-aminolaevulinic acid, methyl 5-aminolaevulinate and hexyl 5-aminolaevulinate on normal human skin. Br J Dermatol 2006; 155:791-9.
37. Collaud S, Juzeniene A, Moan J, Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents 2004; 4:301-16.
38. Gerscher S, Connelly JP, Griffiths J et al. Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo. Photochem Photobiol 2000; 72:569-74.
39. Peng Q, Soler AM, Warloe T et al. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001; 62:140-5.
40. Moan J, Ma L, Iani V et al. Influence of light exposure on the kinetics of protoporphyrin IX formation in normal skin of hairless mice after application of 5-aminolevulinic acid methyl ester. J Invest Dermatol 2005; 125:1039-44.
41. Wennberg AM, Larkö O, Lönnroth P et al. Delta-aminolaevulinic acid in superficial basal cell carcinomas and normal skin - a microdialysis and perfusion study. Clin Exp Dermatol 2000; 25:317-22.
42. Grapengiesser S, Ericson M, Gudmundsson F et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27:493-7.
43. van den Akker JT, Iani V, Star WM et al. Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol 2000; 72:681-9.
44. Soler AM, Angell-Petersen E, Warloe T et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000; 71:724-9.
45. Robinson DJ, de Bruijn HS, Star WM et al. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol 2003; 77:319-23.